Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report of intergroup study 0034
George E. Laramore(University of Washington Medical Center), Bruce H. Campbell(Johns Hopkins University), Robert E. Haselow(University of Washington Medical Center), Charles Scott(American College of Radiology), Thomas J. Ervin(Harvard University), Dorit Elisabeth Schuller(The Ohio State University), Richard Wheeler(University of Washington Medical Center), James G. Schwade(University of Washington Medical Center), John R. Jacobs(University of Washington Medical Center), Muhyi Al‐Sarraf(University of Washington Medical Center), R. Gahbauer(University of Washington Medical Center)
International Journal of Radiation Oncology*Biology*Physics
January 1, 1992
Cited by 413
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k